Mustafa Pehlıvan

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Meletios Α. Dimopoulos, Evangelos Terpos, Mario Boccadoro et al. · The Lancet Oncology · 2021 · 316 citations

Hematological Malignancy, Oncology, Dexamethasone Versus Pomalidomide +7

Clinical and prognostic features of plasmacytomas: A multicenter study of Turkish Oncology Group‐Sarcoma Working Party

Ö. Karakoyun Çelik, Yücel Pak, Ayşe Nur Demiral et al. · American Journal of Hematology · 2008 · 68 citations · Full text

TNF-alpha, TGF-beta, IL-10, IL-6 and IFN-gamma gene polymorphisms as risk factors for brucellosis.

İlkay Karaoğlan, Sacide Pehlıvan, Mustafa Namıduru et al. · PubMed · 2009 · 53 citations

Immunodeficiencies, Immunology, Genetic Epidemiology +17

Can mycoplasma-mediated oncogenesis be responsible for formation of conventional renal cell carcinoma?

Mustafa Pehlıvan, Sacide Pehlıvan, Hüseyin Önay et al. · Urology · 2005 · 36 citations

Urology, Genitourinary Cancer, Mycoplasma-mediated Oncogenesis +6